Novavax Inc
Symbol: NVAX (NASDAQ)
9.64
▲ (2.17%) 0.205
Company Description:
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Key Stats
- Today's Open: $9.48
- Today's High: $9.884
- Today's Low: $9.285
- Today's Volume: 7.21M
- Yesterday Close: $9.43
- Yesterday High: $9.645
- Yesterday Low: $8.59
- Yesterday Volume: 8.75M
- Last Min Volume: 72
- Last Min High: $9.635
- Last Min Low: $9.635
- Last Min VWAP: $9.635
Company Profile
- Name: Novavax Inc
- Website: https://www.novavax.com
- Listed Date: 1995-12-05
- Location: GAITHERSBURG, MD
- Market Status: Active
- CIK Number: 0001000694
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $1.56B
- Round Lot: 100
- Outstanding Shares: 162.42M
- Asset Type: CS
RECENT FILINGS FOR NVAX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-06 | 8-K | View |
| 2025-08-06 | 10-Q | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-11 | 8-K | View |
| 2025-05-27 | 8-K | View |
| 2025-05-19 | 144 | View |
| 2025-05-19 | 8-K | View |
| 2025-05-08 | 8-K | View |
Latest News on NVAX